Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Several other analysts also recently issued reports on the stock. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. Piper Sandler reaffirmed an overweight rating and set a $5.00 price target on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. Finally, Canaccord Genuity Group decreased their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research report on Thursday, May 16th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus price target of $14.83.

Aptose Biosciences Stock Performance

APTO opened at $0.57 on Wednesday. Aptose Biosciences has a 1 year low of $0.55 and a 1 year high of $5.10. The firm has a 50 day moving average price of $0.84 and a 200 day moving average price of $1.37. The company has a market cap of $10.29 million, a PE ratio of -0.09 and a beta of 1.26.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.09. On average, sell-side analysts predict that Aptose Biosciences will post -2.62 earnings per share for the current year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.